Market Overview:

The Brain Cancer Diagnostics Market size is estimated at USD 2.41 Billion in 2024, and is expected to reach USD 4.53 Billion by 2032, growing at a CAGR of 8.2% during the forecast period (2024-2032).

The increasing brain cancer cases and advances in diagnostic technologies are fuelling the growth of the global brain cancer diagnostics market. Brain cancer, which represents abnormal cell growth in the brain tissues, is dangerous in this respect because the brain controls certain vital functions in the body. Therefore, a timely diagnosis along with accuracy would be more than necessary for the right treatment and better patient outcome. The surging awareness of neurological disorders coupled with the increasing demand for non-invasive diagnostic procedures has led to innovation in diagnostic methods such as imaging techniques, molecular testing, and biopsy procedures.

Early detection of brain cancers is now possible owing to advancements in imaging technology and evaluation instruments such as MRI, CT, and PET scans. New hopes for patient management were also sparked off by advancements in molecular diagnostics that helped explain the genetic abnormalities or biomarkers of brain tumours and how treatment plans could be developed in accordance with the findings. Increasing health-care spending, on-going R&D, and tie-ups between diagnostic technology providers and health-care facilities are also driving market growth.

Increasing incidence cases of brain cancer such as glioblastomas and other forms of malignant brain tumours are a major driving force for advanced diagnostic tools. Factors such as healthcare providers emphasizing early detection will continue to drive the brain cancer diagnostics market. In addition, advances in new diagnostics and precision medicine promise to provide new opportunities in the field. Treatment and management of brain cancer may become more targeted on account of this developing prospect.

Worldwide Brain Cancer Data 2022:

Source: Company Publications, Primary Interviews, and IMIR Market Research Pvt. Ltd. Analysis

Market Dynamics - Market Drivers

Increasing Incidence of Brain Cancer

The increased incidence of brain cancer across the globe is one major driver for the worldwide market for brain cancer diagnostics. The incidence rate of some brain cancers such as glioblastoma and astrocytoma has been on the rise over the years, thus the demand for good and accurate diagnosing techniques. More cases are being reported due to increasing exposure by individuals to risk factors such as increased radiation and environmental pollutants as well as the ever-increasing aging population. Moreover, better healthcare infrastructure and knowledge result in earlier diagnosis, which, in turn, boosts the demand for molecular diagnostic and advanced imaging technologies. The diagnostics of brain cancers are critical in modern health care since the early stages are crucial for effective treatment.

Technological Advancements in Diagnostics

The market for cerebrum disease diagnostics is generally determined by the speedy specialized improvements in demonstrative instruments. Cerebrum cancer discovery and checking has been changed by state of the art imaging advancements like Positron Discharge Tomography (PET), Processed Tomography (CT), and Attractive Reverberation Imaging (X-ray). Furthermore, accuracy medication has been made conceivable by the advancement of atomic diagnostics, which incorporates hereditary and biomarker-based tests, taking into consideration more individualized treatment plans. Medical care experts are utilizing these innovations all the more every now and again on the grounds that they empower painless and more exact diagnostics. It is guessed that continuous innovative work in this space would move market extension significantly more.

Market Opportunities

Growing Adoption of Personalized Medicine

On the lookout for cerebrum malignant growth diagnostics, the developing pattern toward individualized care offers a significant open door. Modifying therapy regimens as per a patient's hereditary creation is known as customized medication, and it is especially relevant on account of mind malignant growth, where specific changes and biomarkers habitually decide the best strategy. Upgrades in hereditary profiling and atomic diagnostics have made it feasible for clinical experts to convey more specific medicines, which has worked on understanding results. Drug and biotech firms are putting resources into diagnostics that can assist with the early ID and therapy of cerebrum malignant growth because of the expanded revenue in this subject, setting out new open doors for market development.

Rising Investment in Research and Development

Another significant market potential is the increase in public and private sector spending on research and development (R&D). Projects to improve the diagnosis of brain cancer are receiving more and more financing from governments, medical institutions, and pharmaceutical firms. Those R&D projects are aimed at developing new strategies including liquid biopsies and AI-powered diagnostic instruments while improving current diagnostic methods. Continued research and development work should yield innovative diagnostic solutions that may hopefully make diagnostics more accurate and less time and money-consuming for brain cancer. As such, the booming long-term growth in the market can be expected.

Market Restraining Factors

High Cost of Diagnostic Procedures

High priced advanced diagnostic technology is also considered one of the major barriers to the global market for brain cancer diagnosis. Procedures that are highly priced include MRIs and PET scans and the cost of molecular testing, with most of these charges incurred by patients located in underdeveloped areas with minimal insurance coverage and healthcare infrastructure. High costs may mean that most patients and medical professionals are at a disadvantage, making it harder to get on time and accurate diagnoses. While the latest technologies may have enhanced the diagnosis accuracy, the cost may prevent widespread application since such technologies are expensive, thus making them unaffordable in many low-resource settings.

Limited Availability of Specialized Diagnostic Centres

The other important market barrier is the availability of few specialized diagnostic facilities, particularly in the lower and rural regions. Most brain cancer diagnostics require modern tools and highly qualified specialists for proper interpretation of the results. On the other hand, many healthcare facilities do not possess such infrastructure and knowledge, especially in low- and middle-income countries. This delays detection and treatment by creating a gap in access to modern tests. The lack of physical diagnostic centres is one of the major hindrances for patients in obtaining prompt and accurate diagnoses, although telemedicine and other tele-diagnostic facilities have started to gain popularity. The solving of this issue is crucial for the broader usage of diagnostic technologies in the case of brain cancer.

Segmentation Analysis

The market scope is segmented because of by Diagnosis Type, by Cancer Type, by Biomarker Type.

By Diagnosis Type

Based on the Diagnosis Type of the market is segmented into Imaging Tests {Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan}, Biopsy {Needle Biopsy, Surgical Biopsy}, Molecular Testing, Electroencephalogram (EEG), Lumbar Puncture (Spinal Tap).

In the diagnostic type segments, Imaging Tests, which include Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scans, and Positron Emission Tomography (PET) scans, dominated the global brain cancer diagnostics market. Critical to the early detection, localization, and monitoring of a tumour, imaging has been the primary diagnostic mode. MRI is especially regarded as the gold standard for diagnosis of brain tumours, with particularities of high-resolution imaging which could visualize tissues in the brain in great detail. This would be non-invasive, widely available, and detectable even at the earliest stages.

The use of CT scans is also highly valued because they enable immediate imaging, especially when dealing with emergency cases. PET scans are also important for the evaluation of tissue metabolism in the brain and serve as a supportive means for the differentiation between tumour growths and benign growths.

All these imaging techniques together provide adequate information necessary not only for diagnosis but also for treatment planning. Moreover, an advancement in imaging modalities technology including functional MRI and advanced PET-CT scanners have added to enhancing the accuracy of diagnosis, which has been a contributing factor to the growth and dominance of this segment in the brain cancer diagnostics market.

By Cancer Type

Based on the Cancer Type of the market is segmented into Glioblastoma, Astrocytoma, Meningioma, Oligodendroglia, Ependymal.

Market share for the type of brain cancers diagnosed is dominated by glioblastoma. Glioblastoma, otherwise referred to as glioblastoma multiform (GBM), is the most aggressive and common type of malignant brain tumour, constituting a large percentage of all diagnosed cases of brain cancers. Given its highly invasive nature, rapid progression, and multidrug resistance, early diagnosis and accuracy are essential in managing the patient. Because of its prevalence and the urgency of needing advanced diagnostic techniques, glioblastoma has become the focus of further research, and therefore drives interest in innovative imaging technologies, such as MRI and CT scans, as well as molecular testing, which assists in determining certain mutations commonly associated with this tumour.

The complexity and severity of glioblastoma necessitate continuous monitoring and advanced diagnostic tools to measure tumour progression and assess responses to treatment; hence, it is increasingly dominating the market. Additionally, healthcare providers are investing in early detection methods in the case of glioblastoma due to its poor prognosis as well as the high rate of recurrence, which would improve survival rates thus this segment is the largest in the brain cancer diagnostics market. High incidence and lethality of glioblastoma highlight the necessity for advanced diagnostics, which would leave no room for competition from other types such as astrocytoma, meningioma, oligodendroglia, and ependymal.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. The market for brain tumour diagnostics in North America is predicted to hold a significant share of the market over the course of the forecast period. It is reported that the United States will dominate the market. This can be attributed to the development of the healthcare sector as well as the rising awareness of cutting-edge technologies among the local population. As per the American Brain Tumour Association, in 2021, around 84,000 individuals were diagnosed with primary brain tumours, and nearly 18,000 people died of primary malignant brain tumours. Moreover, the same source estimates that during 2021, over 28,000 paediatric brain tumour diagnoses will be done in the US. The advance of this market is likely to be spurred by the rising incidence of brain tumours.

In addition, the leading industry players in the region are expected to launch and introduce advanced diagnostics devices in the country, which would aid the growth of the market. As an instance, FDA approved ADM Diagnostics Inc.'s CorInsights MRI in December 2021. For radiologists, neurologists, and clinical researchers, CorInsights MRI offers quantities information about the volume of brain tissue. Such developments are driving the growth of the regional market.

List of Companies Profiled

• Hitachi, Ltd.
• Hologic, Inc.
• GE Healthcare
• Fujifilm Corporation
• Koninklijke Philips N.V.
• Thermo Fisher Scientific
• Amgen Inc.
• AstraZeneca
• Bayer AG
• NantOmics
• Hoffmann-La Roche Ltd
• Eisai Co., Ltd
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Shimadzu Corporation
• Siemens Healthineers AG

Key Industry Developments

In June 2024, AstraZeneca announced the successful acquisition of clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc., which focuses on the development of next-generation radio conjugates (RCs). The acquisition is AstraZeneca's major step forward to fulfil its ambition of transforming the cancer treatment and results for patients by replacing traditional regimens such as chemotherapy and radiotherapy with more targeted treatments.

In January 2024, Siemens Healthiness and City Cancer Challenge (C/Can) are expanding the geographical and technological scope of their partnership for the long term, building on their existing collaboration to enable more timely cancer diagnosis and treatment, and increase survivorship for patients in low- and middle-income countries.

Report Coverage

The report will cover the qualitative and quantitative data on the global Brain Cancer Diagnostics Market. The qualitative data includes latest trends, market players’ analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Brain Cancer Diagnostics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Brain Cancer Diagnostics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Brain Cancer Diagnostics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Brain Cancer Diagnostics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Brain Cancer Diagnostics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Brain Cancer Diagnostics Market valued?
• Which region has the largest share in 2024 for the global Brain Cancer Diagnostics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Brain Cancer Diagnostics Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Billion

Brain Cancer Diagnostics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: